The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
 
Jerome Fayette
Honoraria - Bristol-Myers Squibb; Hookipa Pharma; Merck Serono; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Elevar Therapeutics; Hookipa Pharma; ITeos Therapeutics; Merck Serono; Merck Sharp & Dohme; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Florian Clatot
Honoraria - AstraZeneca; AstraZeneca; BMS; BMS; BMS; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD
Consulting or Advisory Role - BMS; Lilly; Lilly; Merck Serono; Merck Serono; MSD; Novartis; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; BMS; Merck Serono; Novartis; Novartis; Pfizer; Roche
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Boehringer Ingelheim; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Merus; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); Tolremo (Inst); VCN Biosciences (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Esma Saada
Consulting or Advisory Role - Merck; MSD
Research Funding - AstraZeneca (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Merck Serono; MSD
 
Carla M.L.- van Herpen
Consulting or Advisory Role - National Institute for public health and the environment
Research Funding - Multiple...
 
Thibault Mazard
Consulting or Advisory Role - Merck Serono; Pierre Fabre; SERVIER
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Sanofi
 
Cesar Augusto Perez
Consulting or Advisory Role - BeiGene; EMD Serono
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); Elevation Oncology; Elpiscience (Inst); Genentech; Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Merus; Mirati Therapeutics (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Tachyon Therapeutics; Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; AVEO; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Immodulon Therapeutics; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; Incyte; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Virginia Arrazubi Arrula
Consulting or Advisory Role - BeiGene; MSD
Speakers' Bureau - BeiGene; Lilly
Travel, Accommodations, Expenses - Merck; MSD
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Consulting or Advisory Role - Astellas Pharma (I); Bristol-Myers Squibb (I); Celgene (I); SERVIER (I)
Research Funding - Amgen (Inst); Artios (Inst); Basilea (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HUTCHMED (Inst); Jiangsu Hengrui Medicine (Inst); Mereo Biopharma (Inst); Merus (Inst); Nurix (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent No: 1716712.3 pending (I)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Bristol-Myers Squibb (I); Caris Life Sciences; Repare Therapeutics; Sapience Therapeutics; Seagen; SERVIER (I)
Other Relationship - European Organisation for Research and Treatment of Cancer (EORTC)
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Assuntina G. Sacco
Employment - Moores Cancer Center
Consulting or Advisory Role - Bicara Therapeutics
Research Funding - Bicara Therapeutics (Inst); Merck (Inst); Nektar (Inst)
 
Amir Harandi
No Relationships to Disclose
 
J.P. De Boer
Consulting or Advisory Role - Lilly; MSD
 
Jessica Hellyer
Consulting or Advisory Role - Tempus
 
Eduardo Pennella
Employment - Merus
Stock and Other Ownership Interests - Merus
 
Andrew K. Joe
Employment - Merus NV
Leadership - Merus NV
Stock and Other Ownership Interests - Merus NV
Travel, Accommodations, Expenses - Merus NV
 
Amaury Daste
Consulting or Advisory Role - BMS; Merck; MSD
Travel, Accommodations, Expenses - BMS; Merck